Displaying 341 - 360 of 4770
Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban
Federal Trade Commission and Justice Department Hold Trilateral Meeting with Competition Enforcers from Mexico and Canada
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
FTC Announces 2024 Update of Size of Transaction Thresholds for Premerger Notification Filings
FTC Announces 2024 Jurisdictional Threshold Updates for Interlocking Directorates
Syngenta and Corteva, FTC v.
The Federal Trade Commission and state partners have filed a complaint in federal court alleging that pesticide manufacturers Syngenta Crop Protection and Corteva, Inc. have used so-called “loyalty” programs to block and restrict generic competition from pesticide markets, leaving farmers to pay elevated prices for crop protection. The complaint seeks to bar Syngenta and Corteva from continuing these programs and from entering into any similar arrangements in the future, and to restore competition to affected markets.
FTC Publishes Inflation-Adjusted Civil Penalty Amounts for 2024
FTC to Host Virtual Summit on Artificial Intelligence
Statement on FTC Win Securing Temporary Block of IQVIA’s Acquisition of Propel Media
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya Regarding the FY2022 HSR Annual Report to Congress
FTC, DOJ Issue Fiscal Year 2022 Hart-Scott-Rodino Notification Report
John Muir Health/Tenet Healthcare Co., In the Matter of
The Federal Trade Commission sued to block John Muir Health’s proposed $142.5 million deal to acquire sole ownership of San Ramon Regional Medical Center, LLC from current majority owner Tenet Healthcare Corporation, saying the deal will drive up health care costs.
The Commission issued an administrative complaint and authorized a lawsuit in federal court alleging the proposed acquisition will eliminate head-to-head competition between John Muir Health and nearby San Ramon Regional Medical Center.
On December 18, 2023 the FTC and California moved to dismiss their federal court case and the FTC dismissed its administrative challenge following John Muir announcing it would terminate its proposed deal to acquire Tenet’s remaining interest in San Ramon Medical Center.
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics
Sanofi/Maze Therapeutics, Inc., In the Matter of
On December 13, 2023, the FTC moved to dismiss its case challenging the transaction following Sanofi’s decision to terminate its transaction with Maze Therapeutics Inc.
FTC Staff Report Details Key Takeaways from AI and Creative Fields Panel Discussion
Statement Regarding the Termination of John Muir’s Takeover of San Ramon Regional Medical Center from Tenet Healthcare
Displaying 341 - 360 of 4770